For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Alpha-Lipoic Acid?
Alpha-lipoic acid, commonly abbreviated ALA and also called thioctic acid, is an organosulfur compound synthesized in small amounts by humans and many other organisms. It functions primarily as a covalently bound cofactor for mitochondrial enzyme complexes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. These complexes connect glycolysis and the tricarboxylic acid cycle to oxidative phosphorylation, so lipoic acid is directly associated with cellular energy production. In supplement and experimental research, alpha-lipoic acid is also studied as a redox-active molecule because both its oxidized form and its reduced form, dihydrolipoic acid, can participate in antioxidant systems.
Research interest in alpha-lipoic acid spans antioxidant defense, insulin sensitivity, peripheral nerve function, mitochondrial biology, and age-related cellular stress. Clinical studies have particularly examined intravenous and oral preparations in diabetic polyneuropathy, while metabolic studies have investigated whether ALA improves insulin-stimulated glucose disposal. Results vary according to formulation, dose, treatment duration, disease state, and endpoint. Alpha-lipoic acid should therefore be regarded as a research compound with some established clinical-study history rather than as a universal anti-aging intervention or a replacement for standard medical care.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study)
Ziegler, D., Hanefeld, M., Ruhnau, K. J., et al., 2006, Diabetes Care - Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial
Ziegler, D., Ametov, A., Barinov, A., et al., 2006, Diabetes Care - Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis
Ziegler, D., Nowak, H., Kempler, P., et al., 2004, Diabetic Medicine - Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial
Jacob, S., Ruus, P., Hermann, R., et al., 1999, Free Radical Biology and Medicine - Alpha-lipoic acid as a biological antioxidant
Packer, L., Witt, E. H., and Tritschler, H. J., 1995, Free Radical Biology and Medicine